-7 -6 -5 -4 -3 -2 0 03691215182124 Treatment month Adjusted mean change in IPSS from baseline (ITT, LOCF) Tamsulosin -4.8 -4.5 -4.4 -4.3 -4.5 -4.4 -4.7.

Slides:



Advertisements
Similar presentations
Corpus Callosum Damage Predicts Disability Progression and Cognitive Dysfunction in Primary-Progressive MS After Five Years.
Advertisements

For(int i = 1; i
The FREEDOM Study (Impact of Short Daily Hemodialysis on Restless Legs Symptoms and Sleep Disturbances) Source Jaber BL, Schiller B, Burkart JM, et al.
Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.
OnabotulinumtoxinA for Urinary Incontinence from Neurogenic Detrusor Overactivity.
1 MT vs CT: 28 day survival Number at risk CT MT day % Surviving Monotherapy.
Tim Hargreave Dept of Oncology, Edinburgh University The medical management of BPH Dutasteride Taipei July 16, 2005.
Memantine in Vascular Dementia Möbius H.J. and Stöffler A. International Psychogeriatrics 2003, 15 Suppl 1:
Philip J. Barter, et al. Circulation 2011;124:
Reappraisal of Published Randomized LUTS/BPH Clinical Trials –What Have We Learned and Where Do We Stand? 王炯珵 醫師 恩主公醫院泌尿科 Chung Cheng Wang, M.D. Ph.D Department.
Pregabalin Efficacy in Peripheral Neuropathic Pain Results from the first 15 months of an ongoing open-label study in patients with treatment-
The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.
Journal of the American Medical Association (JAMA), 2004, 291:
An introduction to social media: Why this is important for urologists Trends and developments in social media Giacomo Novara, M.D., F.E.B.U. Assistant.
STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.
Parish S, et al. Eur Heart J 2009 [Epub ahead of print]
Effects of Memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised,
Effects of Ranolazine on Angina and Quality of Life Following PCI with Incomplete Revascularization -- The Ranolazine for Incomplete Vessel Revascularization.
The Earlier The Better for BPH Patients with Moderate Symptoms Who at Risk of Progression? New Evidence CONDUCT Study Basuki B. Purnomo.
SILODOSIN: THE DIFFERENTIAL EFFECTS OF A NEW ALPHA BLOCKER
URCE/DUT/0025/13b, Date of preparation: January 2014 For Healthcare Professional Use only Prof. Doddy M. Soebadi.
Benign Prostatic Hyperplasia: Trends in Medical Management
Beta Blockers May be useful in RX of somatic symptoms such as palpitations, sweating, tremor… 20-60mg of Propranalol/day Not used much except in certain.
Volume 59, Issue 2, Pages (February 2011)
Mean Responses on PGI-Improvement Primary Endpoint at Week 12
Baseline Demographic and Clinic Variables According to Office vs 24-Hour or Home BP Giuseppe Mancia, et al. Hypertension 2006;47;
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Figure 5 Types of urinary diversion
Atorvastatin 20 mg (n=25 lesions) Atorvastatin 5 mg (n=25 lesions)
Kantarjian H et al. Cancer 2009;[Epub ahead of print].
Adjusted relative mortality risk
Can Primary Care Physicians Take the Lead in Combating Obesity?
Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.
Change in mean LVMI with erythropoietin alpha hemoglobin maintenance treatment and control/delayed treatment from baseline to 24 months End point Hemoglobin.
Volume 59, Issue 2, Pages (February 2011)
Volume 55, Issue 2, Pages (February 2009)
MAGIC-AF Trial design: Patients with persistent atrial fibrillation (AF) and remaining in AF after pulmonary vein isolation alone were randomized to either.
PREMIER: Rate of hypertension at 18 months
Estimated Number of Cancer Cases (in Thousands) Attributable to Excess Body Mass
Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.
Mancini JG, et al. Am J Cardiol.
Sudhop T. et al. J Lipid Res 2009 Apr 20 [Epub ahead of print]
Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%
What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice?  François Desgrandchamps  European Urology.
Enrollment and Outcomes
Flow chart Settergren M, et al. Eur Heart J [Epub ahead of print]
Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]
Gordon R. Reeves et al. JCHF 2017;j.jchf
Study Participant Flow
RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.
DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.
Patient Disposition James A. de Lemos et al. JAMA 2004; 292:
Tremblay AJ. Et al. J Lipid Res 2009 Mar 22 [Epub ahead of print]
C.G Roehrborn, T McNicholas  European Urology Supplements 
Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]
Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.
Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.
The 6MWT results showing improvement from baseline at 1, 6 and 12 months in patients receiving an implant (mean±SE of mean). The 6MWT results showing improvement.
Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),
Current insulin dose (units/kg/day) during the DCCT/EDIC study by sex (black line for females) (A), DCCT intensive vs. conventional treatment group (black.
Fig. 2. Change in IPSS scores as a measure of treatment effectiveness
Kantarjian HM et al. Blood 2008;112:Abstract 635.
Effect of empagliflozin on efficacy parameters at week 18.
Primary outcome and patient reported secondary outcomes in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia receiving.
Mean change from baseline over time in BILAG score,
FIM total score by study visit (ITT population).
Effectiveness of vaccination for influenza in the current and any of the 3 previous seasons in preventing nonsevere and severe cases of influenza by season,
WOMAC (Western Ontario and McMaster Universities Arthritis Index) symptoms in the operated knee and contralateral knee over time and by treatment. WOMAC.
Effectiveness of vaccination for influenza in the current and 3 previous seasons in preventing nonsevere and severe cases of influenza. Effectiveness of.
Presentation transcript:

Treatment month Adjusted mean change in IPSS from baseline (ITT, LOCF) Tamsulosin Dutasteride Combination Adapted from Roehrborn et al. J Urol 2008;179: CombAT Primary End Point Mean Change in IPSS from Baseline

Treatment month Adjusted mean change in Q max (mL/sec) from baseline (ITT, LOCF) P<0.001 combo vs. tamsulosin P<0.006 combo vs. dutasteride TamsulosinDutasteride Combination Adapted from Roehrborn et al. J Urol 2008;179: CombAT - Secondary End Point: Mean Change in Q max from Baseline

Adapted from Barkin et al. BJU Int 2009 Feb 23 [Epub ahead of print]. CombAT Change in BII Score at Two Years

Adapted from Barkin et al. BJU Int 2009 Feb 23 [Epub ahead of print]. CombAT Change in IPSS Q8 Score at Two Years